Intended for healthcare professionals
Search
Toggle navigation
Current issue
Archive
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
Editorial board
For authors
Advertising
Contact us
News
Web Exclusives
Register
FREE
Sign in
×
Remember me
Not registered?
Forgot your password?
The treatment of moderateto-severe atopic eczema
Thomas F Poyner
Most GPs enjoy dermatology and are enthusiastic to improve their skills and knowledge in order to manage common skin diseases in primary care. The most common dermatological consultation they are faced with is paediatric atopic eczema. This is also reflected in secondary care, with atopic eczema being the most common referral among children. Although most cases of atopic eczema are mild, 14% are moderate and 2% are severe.
Dermatology in practice
2004;
12
(3): 24–26
To continue reading this article, please
sign in
or
register
.
Follow us on
|
|
Latest News
FDA grants approval to Organon’s Vtama cream in atopic dermatitis
EMA committee recommends Galderma’s nemolizumab for prurigo nodularis and atopic dermatitis
LEO Pharma receives MHRA approval for Anzupgo cream in chronic hand eczema
Galderma shares positive phase 3 data for nemolizumab in prurigo nodularis
J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis trial
This site uses cookies in order to function properly and to allow us to improve our service. By using this site you consent to the use of cookies as set out in our
privacy policy